CYBB and prostate carcinoma: Given that NOX2 is expressed highly in human prostate cancers, this study provides novel in vivo evidence for a molecular mechanism activated by the cancer-promoting VEGF pathway, and hence a rationale for therapeutic inhibition of endosomal NOX2 oxidase in prostate cancer.